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Background: Endovascular repair for complex thoracic aortic pathology has emerged over the past decade as an alternative
to open surgical repair. Reports suggest lower morbidity and mortality rates associated with endovascular interventions.
The purpose of this report was to analyze a large single institution experience in endovascular thoracic aortic repair based
on clinical presentation as well as within and outside specific instructions for use.
Methods: Records of all patients undergoing thoracic aortic endografting at our institution were retrospectively reviewed
for demographics, interventional indications and acuity, operative details, and clinical outcomes. Study outcomes were
analyzed by clinical presentation (urgent/emergent vs elective) and aneurysm morphology that was within and outside
specific instructions for use as recommended by the manufacturer.
Results: Between March 2006 and October 2009, 96 patients underwent thoracic endografting for aneurysm (n  43),
transection (n 7), penetrating ulcer (n 11), dissection (n 19; acute 9, chronic 10), pseudoaneurysm (n 11),
or miscellaneous indications (n  5). Endografting was performed with various endografts (Gore TAG: 59; Medtrontic
Talent: 26; Zenith-TX2: 7; Combination: 4.Involvement of the arch (n 42, 43.75%) was treated with subclavian artery
coverage without revascularization in 13 (13.5%), debranching in 20 (20.8%), and fenestration/stenting in 9 (9.38%).
Involvement of the visceral vessels (n 24, 25%) was treated with debranching in 15 (15.6%) or fenestration/stenting in
9 (9.4%). Patients had a mean follow-up of 11.5  10.96 (range: 0-38) months. Overall mortality was 6.25% (n  6).
Mean intensive care unit stay was 6.26 8.55 (range: 1-63, median: 4) days, and hospital stay was 9.97 10.31 (range:
1-65, median: 65) days. Major complications were infrequent and included: spinal cord ischemia (n  6, 6.25%), stroke
(n  6, 6.25%), myocardial infarction (n  3, 3.15%), renal failure (n  6, 6.25%), and wound complications (n  9,
9.38%). Reoperation was required in 13 (13.54%), with early intervention in 2 (2.1%). The vast majority of patients were
discharged directly to home (n  66, 68.8%). There were no significant differences between death (1/49 [2%] vs 5/47
[10.6%], P .07), stroke (3/49 [6%] vs 3/47 [6%], P 1.0), or spinal cord ischemia (3/49 [6%] vs 3/47 [6%], P 1.0)
when comparing urgent/emergent presentation to elective cases, respectively. However, there were significant differences
in death (6/58 [10.5%] vs 0/38 [0%], P  .04) and spinal cord ischemia (6/58 [10.5%] vs 0/38 [0%], P  .04) but not
stroke (5/58 [8.8%] vs 1/38 [2.5%], P .24] when procedures were performed outside the specific instructions for use.
Conclusions: Results of this single-institution report suggest that endovascular thoracic aortic repair is a safe and effective
treatment option for a variety of thoracic pathology including both elective and emergent cases. However, off-label usage
of the devices is associated with a significantly higher risk of mortality and spinal cord ischemia, but the risk still appears
acceptable given the majority of cases were emergent. ( J Vasc Surg 2011;53:926-34.)
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926The introduction of thoracic endovascular aortic repair
TEVAR) has revolutionized the surgical approach to de-
cending thoracic aneurysms.1 TEVAR is consistently asso-
iated with lower perioperative mortality rates and
mproved morbidity including a reduced incidence of
ostoperative neurologic and cardiopulmonary compli-
ations compared to open repair.2-8 Improved outcomes
esult in shorter intensive care unit (ICU) and hospital
tays and faster overall recovery.
While TEVAR is only FDA-approved for descending
horacic aneurysms and more recently, the treatment of pen-
trating ulcers, excellent outcomes have fueled the rapid ex-
ension of this technology to treat additional complex and
cute thoracic aortic pathology.5-8 TEVAR is now widely
ccepted and implemented for the treatment of complex
ortic aneurysms requiring aortic debranching, aortic dissec-
ion, and traumatic aortic injuries. Reported results for TE-
AR in the emergent setting and outside the indications for
se, however, are still preliminary and varied.
The purpose of this report was to analyze a large single
nstitution experience in endovascular thoracic aortic repair
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Volume 53, Number 4 Knowles et al 927based on clinical presentation as well as within and outside
specific instructions for use.
METHODS
Data collection
A retrospective medical record review was performed of
all patients treated with thoracic endografts at our single-
institution between March 2006 and October 2009. Data
collected included demographics, indications for repair,
operative details, and postoperative outcomes. Demo-
graphics collected included pre-existing medical comor-
bidities, prior aortic operations, and indications and ur-
gency of repair. Operative details included blood loss,
endograft type, need for revascularization, and type of
revascularization procedures. Postoperative outcomes eval-
uated included perioperative mortality, ICU and hospital
stay, complications, and final disposition.
Patient selection
A thorough history and physical examination as well as
a computed tomographic angiogram were performed pre-
operatively in all patients. Patients selected for endovascular
thoracic aortic repair were deemed to be high-risk for open
repair based on pre-existing significant medical comorbidi-
ties, coexisting severe injuries, or prior aortic operations.
Patients deemed too high risk for open surgery with pathol-
ogy involving the branched aorta were treated with TEVAR
and aortic revascularization. Indications for elective tho-
racic aortic repair included enlarging aneurysms 5.5 cm
and rapid aneurysm expansion exceeding 5 mm in 6
months, or other asymptomatic pathology. Urgent or
emergent interventions were performed in patients with
acute dissections or evidence of malperfusion, aortic tears
or rupture, and symptoms indicating impending rupture
including back or chest pain. Indications for the repair of
aortic dissection were determined by CT scan and physical
examination findings. Findings of malperfusion impending
rupture, or severe hypertension, despite aggressive medical
therapy were repaired with TEVAR. Acute dissections
found within 14 days after the onset of symptoms were also
repaired. Patients with resolution of symptoms with medi-
cal therapy and asymptomatic chronic dissections were
followed expectantly. Coverage of the left subclavian artery
(LSCA) was performed liberally, with indications for revas-
cularization early in the study period including use of the
left internal mammary artery for coronary artery bypass
grafting, a hypoplastic right vertebral artery, presence of a
functioning arteriovenous fistula in the left upper extrem-
ity, or anomalous left vertebral artery arising from the aortic
arch. Later in the study period, subclavian artery revascu-
larization was routinely performed if the origin was sacri-
ficed due to increasing evidence of spinal cord and cerebro-
vascular protection with this technique.9-12
Patients included in the on-label group were those meet-
ing endoprosthesis indications for use as per FDA guidelines.
Thus, on-label included patients with aneurysmal change and
penetrating ulcers as per endoprosthesis specific indications. mll other etiologies, including any requiring debranching or
enetration were included in the off-label group. Patients with
nvolvement of the orifice of the subclavian artery were in-
luded as on-label regardless of debranching.
perative technique
All procedures were performed in the operating room
nder general anesthesia. Patients were treated with one of
hree approved thoracic endografts: Gore TAG (W. L.
ore and Associates, Flagstaff, Ariz), Zenith TX2 (Cook
edical Inc, Bloomington, Ind), or Talent (Medtronic,
nc, Santa Rosa, Calif). Intravascular ultrasound (Volcano
orporation, San Diego, Calif) was routinely used for
natomic purposes, assessment of landing zones, assess-
ent of true and false lumen, and for aiding in fenestration.
Debranching procedures were performed prior to
EVAR placement, however, all procedures were per-
ormed in a single setting. Branch vessel bypass conduits
onsisted of polytetrafluoroethylene (PTFE) (n  15),
eep vein (n  35), or greater saphenous vein (n  3). All
horacic debranching was performed extrathoracic with
ither deep vein or PTFE. Visceral debranching was per-
ormed with deep vein, greater saphenous vein, or PTFE.
ultivessel visceral debranching was common in hybrid
rocedures. LSCA fenestrations via a laser in situ technique
ere performed in four patients, with two involving stent
lacement through the fenestration. Renal stents were placed
n nine dissection patients for renal protection or renal failure;
owever, none was through fenestrations. Iliac conduits with
emashield 10mmDacron graftswere used to bypass visceral
egments when access vessels were7mmor heavily calcified
nd tortuous preventing adequate access.
Cerebrospinal fluid drains were used selectively in pa-
ients at high risk for spinal cord ischemia given previous
ortic surgery or need for extensive coverage of the thoracic
orta to maintain a cerebrospinal pressure of10 mmHg.
ll drains were removed on postoperative day three, unless
aralysis was present.
ata analysis
Patients were separately analyzed by urgency of repair
elective vs emergent) and by indication for repair (FDA
pproved vs off-label). Results are reported as a mean the
tandard deviation. Differences between two groups were
nalyzed using the Student t test. A P value of .05 was
onsidered statistically significant.
ESULTS
atients
Ninety-six patients underwent TEVAR in one of the
hree University of Texas – Southwestern hospitals during
he study inclusion period. Demographics are summarized
n Table I. Overall, there was a slight male predominance
nd a mean age of 66 years. Etiology for repair was for
neurysmal degeneration (n 43, 44.8%) with 11 of these
atients treated for acute rupture (11/43, 25.6%), trau-
atic aortic transection (n  7, 7.3%) (Fig 1), penetrating
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April 2011928 Knowles et alulcer (n  11, 11.5%), dissection (n  19, 19.8%; acute 
9, chronic  10), pseudoaneurysm (n  11, 11.5%), or
miscellaneous indications (n  5, 7.3%). This miscella-
neous group included repair for two aberrant right subcla-
vian artery aneurysms, an aortic atheroma, aortic stenosis,
and coarctation. Twenty-seven patients had a history of
previous aortic surgery. This group included four patients
with previous ascending arch repair, 10 previous open
abdominal aortic aneurysm repairs, one aortic valve replace-
ment, three endovascular aneurysm repair EVAR, one TE-
VAR with abdominal aortic aneurysm (AAA) and SC by-
pass, three aortobifemoral repairs, one mesenteric bypass,
four previous descending arch repairs, one thoracoabdomi-
nal aneurysm repair, one neo-aortoiliac system, and one
previous coarctation repair. Lumbar drains were used in 23
patients (23.96%) (Table II).
Interventions were performed with a variety of thoracic
endografts including the Gore TAG in 59 patients (61%),
Talent graft in 26 patients (28%), and Cook TX2 in seven
Fig 1. Traumatic aortic transections remain an off-labe
The patients above were performed emergently for acute
(a, b) and in the descending thoracic aorta (c, d).patients (7%). Four of these patients were treated with a aombination of these endografts. Forty-two patients
43.75%) had involvement of the arch (which included the
ubclavian artery origin), of which 20 patients (20.8%)
nderwent arch debranching and 24 (25%) had involve-
ent of the visceral aorta with 15 (15.6%) requiring deb-
anching (Fig 2). The vast majority of patients undergoing
ortic arch debranching (17 of 20; 85%) were patients with
neurysmal disease requiring proximal endograft extension,
hereas the majority of the patients undergoing visceral
ebranching had dissections involving those vessel origins
11 of 15; 73.3%) (Table II). All but one patient underwent
xtrathoracic debranching, requiring amedian sternotomy for
pen repair of the ascending arch aneurysmwith endovascular
reatment of the symptomatic descending dissection. She
eveloped transient renal failure and required a return to the
perating room to drain a pericardial effusion. No patients
ndergoing hybrid repairs for thoracoabdominal aneurysms
equired a thoracoabdominal incision.
Technical success was 100% (no open conversions) with
ation for thoracic endovascular aortic repair (TEVAR).
atic aortic transection with pseudoaneurysm in the archl indic
traumn overall 30-day mortality of 6.25% (n  6). Two acute
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Volume 53, Number 4 Knowles et al 929reinterventions were required. The first patient was treated for
an aberrant right subclavian artery aneurysm and, on postop-
erative day one, was taken back to the operating room for an
endovascular repair of a blowout of the right subclavian artery
stumpwith a proximal cuff placement. The second sustained a
small inferior vena cava tear during the initial procedurewhich
resulted in hemoperitoneum requiring open caval repair on
postoperative day one. There were 13 total reoperations
within the initial hospitalization, including, four colectomies
for ischemic colitis (one patient’s family declined), endovascu-
lar repair of an external iliac aneurysm, endovascular repair of
distal graft collapse, repair of a common femoral artery suture
line and drainage of groin hematoma, repair of a common
femoral dissection, repair of a femoral pseudoaneurysm, inci-
sion and drainage of brachial artery access site abscess, and coil
embolization of an LSCA for endoleak after coverage and
Fig 2. The applicability of thoracic endovascular aortic
fenstrations, branched-grafts, or debranching procedure
chronic type B expanding thoracic dissections. The first
fenestration and stenting of the superior mesenteic art
underwent TEVAR with coverage of the left carotid and
subclavian bypasses (c, d).revascularization. There were seven patients that required aeintervention for endoleak during the study period, three for
ype one endoleaks and four for type two endoleaks.
Mean ICU stay was 6.26  8.55 days with a mean
ospital stay of 9.97 10.31 days. Mean follow-up was 11.5
10.96 months (Table III). Overall, 70% of patients had at
east one postoperative complication with respiratory compli-
ations experiencedmost frequently (Table IV). Nonetheless,
he vast majority of patients were eventually discharged to
ome (n 66, 68.8%), a routine discharge, with the remain-
ngbeing sent to skilled nursing facilities, nursing homes, or to
ehabilitation centers (Table III).
mergent vs elective interventions
Forty-seven patients were classified as elective repairs
49%) and the other 49 (51%) were termed urgent or
mergent given their symptoms/findings. Demographics
ir (TEVAR) may be extended with the use of off-label
VAR was performed above, in the elective setting, for
nt had a chronically occluded celiac artery but required
MA) and left renal artery (a, b). The second patient
clavian after performing carotid-carotid and carotid leftrepa
s. TE
patie
ery (S
subre summarized in Table I. Patients undergoing elective
.
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April 2011930 Knowles et alrepair were older with a higher number of serious comor-
bidities compared with those undergoing emergent tho-
racic interventions. Elective patients presented with a
higher average of comorbidities and more frequently pre-
sented with pre-existing hyperlipidemia (P  .03), renal
insufficiency (defined as a creatinine greater than 1.3, P 
.02), and chronic obstructive pulmonary disease (P .03).
Overall, there were no differences in the number of deb-
ranching procedures preformed between the groups; how-
ever, the emergent group had a significantly higher number
Table I. Demographic data
Variable
Total Emergent El
n  96 n  49 n
Mean age (years) 66.4  14.3 63.3  15.3 69.6
Gender (M/F) 55/41 27/22 2
Mean Ao size 6.47  0.95 4.96  1.88 5.25
Comorbidities n (%) 2.07  1.47 1.73  1.37 2.36
CAD 35 (36.5%) 16 (32.7%) 19 (
HTN 67 (69.8%) 34 (69.4%) 33 (
HLD 31 (32.3%) 11 (22.5%) 20 (
COPD 20 (20.8%) 6 (12.2%) 14 (
DM 14 (14.6%) 8 (16.3%) 6 (
CRI 16 (16.7%) 4 (8.2%) 12 (
CVA 11 (11.5%) 3 (6.1%) 8 (
Tobacco use 64 (66.7%) 28 (57.1%) 36 (
Ao,Aortic;CAD, coronary artery disease;COPD, chronic obstructive pulmon
diabetes mellitus; HLD, hyperlipidemia; HTN, hypertension.
aStatistically significant (P  .05).
Table II. Aortic characteristics and debranching
Characteristics
Total
(n  96)
Urgent
(n  49)
Mean aortic size 6.47  0.95 4.96  1.88 5
Prior aortic surgery 31 (32.3%) 12 (24.5%) 1
Spinal drain 23 (24.0%) 11 (22.4%) 1
Vessel involvement
Aortic arch 42 (43.75%) 23 (46.9%) 1
Visceral aorta 24 (25.0%) 14 (28.6%) 1
Both 10 (10.4%) 4 (8.2%)
Subclavian coverage 22 (23.0%)b 14 (28.6%)b
Subclavian stenting 7 (7.3%) 3 (6.1%)
Subclavian fenestration 2 (2.1%) 0 (0%)
No revascularization 13 (13.5%) 11 (22.4%)
Debranching 25 (26.0%) 11 (22.4%) 1
Aortic arch 20 (20.8%) 9 (18.4%) 1
Innominate artery 2 (2.0%) 1 (2.0%)
Carotid artery 6 (6.3%) 2 (4.1%)
Subclavian artery 20 (20.8%) 9 (18.4%) 1
Visceral aorta 15 (15.6%) 6 (12.2%)
Celiac artery 4 (4.2%) 4 (10.2%)
Hepatic 16 (16.7%) 6 (12.2%) 1
SMA 14 (14.6%) 8 (16.3%)
IMA 1 (1.0%) 0 (0%)
Renal artery 19 (19.8%) 12 (24.5%)
Visceral stents
Renal 9 (9.4%) 9 (18.4%)
IMA, Inferior mesenteric artery; SMA, superior mesenteric artery.
a,bIncludes two partially covered.of renal artery stents compared with the urgent group (P m01) (Table II). Lengths of ICU and hospital stay were also
quivalent between the groups (Table III). The elective
roup required more transfusions on average (P  .02),
hich is due to the hybrid procedures as they included an
bdominal exploration and usually deep-vein harvest. The
lective group had no significant difference in postoperative
omplications (Table IV).
n-label vs off-label thoracic endografting
Thirty-eight patients were treated on-label for aneurys-
P value
On-label Off-label
P valuen  38 n  58
.5 .03a 74.0  7.87 61.4  15.35 .01a
.63 18/20 37/21 .01a
87 .45 5.70  1.63 4.69  1.88 .01a
42 .03a 2.55  1.77 1.76  1.16 .01a
) .48 17 (44.7%) 18 (31.0%) .17
) .92 27 (71.1%) 40 (70.0%) .84
) .03a 13 (34.2%) 18 (31.0%) .76
) .03a 13 (34.2%) 7 (12.1%) .01a
) .68 7 (18.4%) 7 (12.1%) .42
) .02a 8 (21.1%) 8 (13.8%) .37
.09 4 (10.5%) 7 (12.1%) .88
) .04a 29 (76.3%) 35 (60.3%) .10
sease;CRI, chronic renal insufficiency;CVA, cerebrovascular accident;DM,
tive
47) P value
On-label
(n  38)
Off-label
(n  58) P value
1.87 .45 5.70  1.63 4.69  1.88 .01a
0.4%) .10 13 (34.2%) 18 (31.0%) .76
5.5%) .65 12 (31.6%) 11 (19.0%) .15
0.4%) .49 13 (34.2%) 29 (50.0%) .12
1.3%) .37 0 (0%) 24 (41.4%) .01a
2.8%) .43 0 (0%) 10 (17.2%) .01a
7.0%) .16 8 (21.1) 14 (24.1%)b .73
.5%) .57 0 (0%) 7 (12.1%) .01a
.3%) .16 0 (0%) 2 (3.5%) .31
.3%) .01a 8 (21.1%) 5 (8.6%) .09
9.8%) .38 5 (13.2%) 20 (34.5%) .01a
3.4%) .48 5 (13.2%) 15 (25.9%) .13
.1%) 1.0 0 (0%) 2 (3.5%) .31
.5%) .32 0 (0%) 6 (10.3%) .05
3.4%) .55 5 (13.2%) 15 (25.9%) .58
9.1%) .35 0 (0%) 15 (25.9%) .01a
%) .05 0 (0%) 4 (6.9%) .10
1.3%) .24 0 (0%) 16 (27.6%) .01a
2.8%) .68 0 (0%) 14 (24.1%) .01a
.1%) .35 0 (0%) 1 (1.7%) .35
4.9%) .27 0 (0%) 19 (32.8%) .01a
%) .01a 0 (0%) 9 (15.5%) .01ective
 47
 12
8/19
 1.
 1.
40.4%
70.2%
42.6%
29.8%
12.8%
25.5%
17%)
76.6%
ary diElec
(n 
.25 
9 (4
2 (2
9 (4
0 (2
6 (1
8 (1
4 (8
2 (4
2 (4
4 (2
1 (2
1 (2
4 (8
1 (2
9 (1
0 (0
0 (2
6 (1
1 (2
7 (1
0 (0al disease (n  27) or penetrating ulcers (n  11) of the
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Volume 53, Number 4 Knowles et al 931descending thoracic aorta (40%) while the remaining 58
patients (60%) were treated off-label. Patients treated on-
label were significantly older (P  .01), predominantly
male (P  .01), and had a significantly higher rate of
comorbidities preoperatively (P  .01) including chronic
obstructive pulmonary disease (P  .01) (Table I).
There was a significantly higher mortality rate experi-
enced by the off-label group (P .04). Multisystem organ
failure was the most common cause of early death (n  5,
83.3%) with a cardiovascular event being the cause for the
other. One of the six patients was emergently repaired for
rupture.
The off-label group also suffered a significantly higher
number of postoperative complications (Table IV) which
likely contributed to the increased overall ICU (P  .02)
and hospital stay (P  .01) (Table III). Spinal cord isch-
emia was only experienced in the off-label group (n  6,
6.25%) and resulted in prolonged paralysis in two patients
who both died from operative complications. In these
patients with spinal cord ischemia, the LSCA was not
covered in three patients, partially covered and not revas-
cularized in one patient, and completely covered but not
revascularized in two patients. Four patients had drains
placed preoperatively; the other two had a drain placed
once weakness occurred. Two patients had persistent paral-
ysis, both having drains preoperatively, both felt secondary
to hypotension and multisystem organ failure. One patient
Table III. Postoperative course
Outcomes
Total Emergent E
n  96 n  49 n
ICU stay (days) 6.26  8.55 6.51  7.58 5.7
Hospital stay (days) 9.97  10.31 11.65  11.05 8.1
Intubation (days) 2.7  4.2 1.55  4.49 2.1
Transfusions (#) 1.0  1.4 1.02  2.19 2.8
Routine discharge 66 (68.8%) 36 (73.4%) 30
Follow-up
(months)
11.5  10.96 8.57  10.02 10.3
aStatistically significant (P  .05).
Table IV. Postoperative complications (30 days)
Complication
Total Emergent E
n  96 n  49 n
Death 6 (6.3%) 1 (2.0%) 5
Myocardial infarction 3 (3.1%) 2 (4.1%) 1
Spinal ischemia 6 (6.3%) 3 (6.1%) 3
Paraplegia 2 (2.1%) 0 (0%) 2
Spinal drain 23 (24.0%) 11 (22.4%) 12
Stroke 6 (6.3%) 3 (6.1%) 3
Pneumonia 11 (11.5%) 5 (10.2%) 6
Prolonged ventilation 13 (13.5%) 5 (10.2%) 8
Acute renal failure 6 (6.3%) 2 (4.1%) 4
Ischemic colitis 5 (5.2%) 1 (2.0%) 4
Reintervention 2 (2.1%) 2 (4.1%) 0
aStatistically significant (P  .05).developed transient weakness when the spinal drain was alamped; however, after unclamping, recovered fully. Two
atients, without previous aortic surgery or extensive re-
air, developed spinal cord ischemia and recovered on
lacement of a spinal drain. The off-label group also had a
light trend toward a higher incidence of postoperative
troke but this was not significant (P .24). Out of the six
atients having a perioperative stroke, three patients did
ot have the LSCA covered, two had it covered and not
evascularized, and one had partial coverage. One of the
atients with intentional subclavian artery coverage with-
ut revascularization experienced intraoperative right
emiparesis upon awakening from anesthesia. He under-
ent emergent carotid-subclavian bypass, with partial res-
lution of symptoms.
Higher rates of ventilatory failure (P .01) and longer
entilator times observed in the off-label group required
racheostomies in five patients with two patients requiring
lacement in an outpatient facility while still on the venti-
ator. This is despite the higher prevelance of chronic
bstructive pulmonary disease (COPD) in the on-label
ubgroup. A trend toward a higher rate of pneumonia may
ave contributed to the higher rate of ventilator failure. In
ddition, when the traumatic aortic disruption patients
ere separately analyzed, these patients were noted to have
ignificantly longer intubation times, respiratory complica-
ions, and longer ICU and hospital stays. The increase in
are and poorer outcomes in this group are believed to be
e
P Value
On-label Off-label
P value7 n  38 n  58
.44 .66 3.53  2.81 7.6  10.36 .02a
.81 .11 6.43  4.64 12.05  12.49 .01a
.25 .55 0.29  0.93 2.77  5.91 .01a
.93 .02a 0.66  1.34 2.79  4.7 .01a
%) .35 30 (78.9%) 36 (62.1%) .08
1.61 .43 8.16  10.8 10.29  10.73 .35
e
P value
On-label Off-label
P valuen  38 n  58
%) .07 0 (0%) 6 (10.5%) .04a
) .58 1 (2.5%) 2 (3.5%) 1.0
) 1.0 0 (0%) 6 (10.5%) .04a
) .16 0 (0%) 2 (3.5%) .31
%) .65 12 (30.8%) 11 (19.3%) .15
) 1.0 1 (2.5%) 5 (8.8% .23
%) .65 2 (5.1%) 9 (15.8%) .11
%) .32 1 (2.5%) 12 (21.1%) .01a
) .32 1 (2.5%) 4 (7.0%) .40
) .12 0 (0%) 5 (8.8%) .05
.17 0 (0%) 2 (3.5%) .31lectiv
 4
4  9
7  9
5  5
9  4
(63.8
2  1lectiv
 47
(10.6
(2.1%
(6.4%
(4.3%
(25.5
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April 2011932 Knowles et aling trauma. Increased rates of transfusions in the off-label
group may have been attributable to the visceral debranch-
ing procedures or coincident traumatic injuries.
Ischemic colitis only occurred in the off-label group in
five patients (5.2%), with four receiving resection and one
refusing. All five patients with ischemic colitis died. The
ischemic colitis was felt to be from cardiac/pulmonary
failure in three patients and malperfusion in the other two
patients.
DISCUSSION
TEVAR has been associated with lower perioperative
mortality and morbidity including a reduced incidence of
spinal cord ischemia as compared with open repair for
descending aneurysms in high-risk patients treated in the
elective setting.2-4 Initial device safety and efficacy trials for
the Gore TAG, Talent, and Cook TX2 devices reported
30-day mortality rates ranging from only 1.9% to 2.1%.2,4,13
Continued reports of technical success and favorable pa-
tient outcomes have quickly resulted in technology exten-
sion to treat acute aortic pathology in the emergent setting.
These patients, including those with aortic aneurysm rup-
ture, traditionally have excessive morbidity and mortality,
which are difficult to accept. Further, extension of this
technology to treat aortic pathology outside the labeled use
of these grafts including complicated aneurysms of the
branched aorta, type B dissections, traumatic aortic disrup-
tions, and pseudoaneurysms have been advocated for pa-
tients who are high-risk or require emergent repair. In this
study, we compared the short-term outcomes for patients
requiring emergent repair with those repaired electively and
reported our outcomes for those repaired off-label with
those repaired according to the FDA indications.
Emergent repair was not associated with an increased
morbidity or mortality rate. In fact, patients in the emer-
gent group had similar postoperative morbidity rates and
lower mortality compared with those repaired electively.
The increased mortality in the elective group, albeit not
significant, was likely attributable to the fact that more
complex hybrid repairs for thoracoabdominal aneurysms
were performed in the elective group. There was also a
significantly higher number of comorbidities in the elective
group. Importantly, when reviewing patients treated for
rupture in this study, mortality was 10%, with six repaired
outside the approved FDA indications, a gross improve-
ment over the reported 27% to 28% reported after open
repair of ruptures.14,15
All deaths occurred in patients treated off-label for
extensive disease accounting for the increased 30-day mor-
tality of 6.25% reported in this study. Of the six patients
that died, three had extensive disease with three of these
patients requiring extensive visceral debranching, two re-
quiring fenestrated visceral stenting, and the last requiring
celiac artery sacrifice (although the latter patient had, in
fact, a right replaced hepatic artery). In addition, one of the
patients had baseline renal failure, three had a history of
aortic surgery, and one was ruptured on presentation.
When considering inclusion criteria as per the Gore TAG, salent, and Cook TX2 studies only, our 30-day mortality
as 0%. The higher mortality, however, should not be
onsidered an argument against off-label use. Rather, it
hould be noted that open repair of these same patients has
een associated with even higher mortality rates and that
his is a significant improvement in outcomes.16,17 Future
se of branched and fenestrated grafts are an emerging
reatment alternative to hybrid procedures and could offer
benefit in morbidity and mortality, removing the need for
xtensive open visceral bypasses.18
Prior reports have indicated that complicated type B
issections with clinical evidence of malperfusion, rupture,
r recalcitrant hypertension experience mortality rates close
o 30%.19-21 This is in sharp contrast to our 0% mortality in
his group. We experienced a similar improvement in out-
omes after endovascular repair of traumatic aortic disrup-
ions with 0% mortality, paraplegia, and stroke, a marked
eduction compared with open repair of these injuries.22-25
ncreased pulmonary complications in this latter group are
ikely related to the chest trauma sustained by these patients
t time of initial injury and may be unavoidable. Similar
utcome improvements after endovascular repair of the
horacic aorta compared to open surgery for both these
ubgroups have been previously reported. Specifically,
arsa et al reported a 2% 30-day mortality, 0% stroke, and
% paralysis rate in 55 patients with acute and chronic
issections of the thoracic aorta repaired endovascularly,8
nd similar outcomes have been reported by other investi-
ators after repair of aortic transactions.24-26 Recently,
haikof et al presented data on patients with repairs for
seudoaneurysm, penetrating ulcer and miscellaneous rea-
ons, with excellent results: 0% mortality, paralysis, or
troke.27 In our data, we had one patient who experienced
stroke (9.1%) and later died (9.1%) in the pseudoaneu-
ysm group.
Overall, while complicated patients requiring off-label
horacic endografting required longer ICU and hospital
tays, higher transfusion requirements, and experienced
igher mortality and morbidity including increased respi-
atory and neurologic complications, compared with the
atients repaired on-label, these patients still experienced a
ignificant benefit compared with reports of patients under-
oing open surgery. In fact, reports of open thoracic aortic
epair indicate transfusion requirements in up to 84% of
atients and ventilatory failure in 33%,28 which is signifi-
antly higher than the 35% transfusion rate and 11% venti-
atory failure rate reported here. Average follow-up was
1.5  10.96 months, which is likely attributable to the
ertiary nature of the medical center and short/recent date
f study.
Our data also continue to support the routine revascu-
arization of the subclavian artery when the origin of this
essel is sacrificed during repair.9-11 Spinal ischemia oc-
urred in six patients (6.25%) and was permanent in two
atients who subsequently died from multisystem organ
ailure. Cerebrovascular events occurred in an additional six
ho were all treated off-label. Fifty-percent of patients with
pinal cord ischemia and 50% of those experiencing stroke
R1
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vascularization, as they were early in study period, before
revascularization of the vessel was routine. After our change
in practice, one patient developed spinal ischemia and
another had a stroke despite revascularization. One of the
patients who initially underwent coverage of the LSCA,
awoke with hemiparesis and underwent an emergent revas-
cularization. One patient experienced transient spinal cord
ischemia and another experienced a stroke despite prophy-
lactic revascularization with coverage of the LSCA. Overall,
three of the 20 patients (15%) who underwent coverage of
the LSCA without revascularization suffered stroke. In
addition, the higher rates of spinal cord ischemia experi-
enced in this study may be partially attributable to the high
number of patients who had undergone prior major aortic
surgery (n 27, 28%), renal insufficiency (n 16.7%), and
inclusion of large, type four thoracoabdominal aneurysms
requiring extensive coverage of the aorta which are all
independent predictors of SCI.29 Notably in the latter
group, patients with type four thoracoabdominal aneu-
rysms, we experienced a 2.1% paraplegia rate which is still
an improvement over the 3.4% rate reported after open
surgical repair.7
In conclusion, TEVAR is associated with improve-
ments in mortality, stroke, paraplegia, and other complica-
tions compared with open repair. Emergent repair for acute
thoracic aortic pathology may obtain results equivalent to,
or improved upon, those results obtained with TEVAR in
high-risk patients undergoing elective repair. As emergent
open surgical repair of acute aortic pathology is associated
with significantly increased morbidity and mortality than in
the elective setting, these patients have much to gain by
endovascular interventions and this approach should be
strongly considered in this subgroup. Off-label use of tho-
racic endografting is higher risk than standard TEVAR;
however, results continue to be improved compared with
open repair. Further, given increased familiarity with TE-
VAR techniques and advances in endovascular technology,
continued improvements in outcomes following TEVAR
can be expected.
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